OverviewSuggest Edit

NGM Biopharmaceuticals is a drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. It focuses on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
TypePublic
Founded2007
HQSouth San Francisco, US
Websitengmbio.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2019)186(+22%)
Job Openings23
Revenue (FY, 2019)$103.5 M(-4%)
Share Price (Oct 2020)$16.3 (-1%)
Cybersecurity ratingCMore

Key People/Management at NGM Biopharmaceuticals

William J. Rieflin

William J. Rieflin

Executive Chairman
Jin-Long Chen

Jin-Long Chen

Founder and Chief Scientific Officer
Alex DePaoli

Alex DePaoli

Senior Vice President, Chief Translational Officer
Marc Learned

Marc Learned

Vice President, Research Operations
Hsiao D. Lieu

Hsiao D. Lieu

Senior Vice President, Chief Medical Officer
Valerie Pierce

Valerie Pierce

Senior Vice President, General Counsel and Chief Compliance Officer
Show more

NGM Biopharmaceuticals Office Locations

NGM Biopharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
333 Oyster Point Blvd
Show all (1)

NGM Biopharmaceuticals Financials and Metrics

NGM Biopharmaceuticals Revenue

NGM Biopharmaceuticals's revenue was reported to be $103.54 m in FY, 2019
USD

Revenue (Q2, 2020)

19.8m

Net income (Q2, 2020)

(25.6m)

EBIT (Q2, 2020)

(25.5m)

Market capitalization (19-Oct-2020)

1.1b

Closing stock price (19-Oct-2020)

16.3

Cash (30-Jun-2020)

249.3m
NGM Biopharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

77.1m108.7m103.5m

Revenue growth, %

41%

General and administrative expense

14.8m17.3m23.6m

R&D expense

79.7m95.7m129.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

25.6m25.3m21.6m24.4m19.8m

General and administrative expense

5.4m6.2m5.6m6.6m6.8m

R&D expense

29.5m28.8m29.0m38.4m38.5m

Operating expense total

34.9m35.0m34.6m45.0m45.3m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

25.6m56.9m245.6m

Prepaid Expenses

1.8m4.3m5.5m

Current Assets

175.5m214.6m355.2m

PP&E

24.9m23.9m19.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

47.3m265.1m303.0m257.0m249.3m

Prepaid Expenses

5.7m5.3m7.7m9.1m7.4m

Current Assets

199.1m368.3m364.3m338.3m322.6m

PP&E

23.3m22.2m20.5m18.3m17.3m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(14.2m)(493.0k)(42.8m)

Depreciation and Amortization

6.4m7.2m7.6m

Accounts Payable

(4.2m)3.5m3.6m

Cash From Operating Activities

(17.4m)(7.6m)(41.2m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(8.3m)(15.9m)(26.9m)(19.1m)(44.7m)

Depreciation and Amortization

2.0m3.9m5.8m1.7m3.4m

Accounts Payable

(1.2m)(2.5m)(1.3m)(5.3m)(6.9m)

Cash From Operating Activities

(12.1m)(19.9m)(26.6m)(19.1m)(38.3m)
USDFY, 2017

Financial Leverage

-2.1 x
Show all financial metrics

NGM Biopharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

NGM Biopharmaceuticals Online and Social Media Presence

Embed Graph

NGM Biopharmaceuticals News and Updates

Global Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma

Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Primary Sclerosing Cholangitis - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. Primary Sclerosing Cholangitis - Market Insights, Epidemiology and Forecast to 2030 delivers an in-depth…

NGM Biopharmaceuticals Blogs

NGM Biopharmaceuticals Frequently Asked Questions

  • When was NGM Biopharmaceuticals founded?

    NGM Biopharmaceuticals was founded in 2007.

  • Who are NGM Biopharmaceuticals key executives?

    NGM Biopharmaceuticals's key executives are William J. Rieflin, Jin-Long Chen and Alex DePaoli.

  • How many employees does NGM Biopharmaceuticals have?

    NGM Biopharmaceuticals has 186 employees.

  • What is NGM Biopharmaceuticals revenue?

    Latest NGM Biopharmaceuticals annual revenue is $103.5 m.

  • What is NGM Biopharmaceuticals revenue per employee?

    Latest NGM Biopharmaceuticals revenue per employee is $556.7 k.

  • Who are NGM Biopharmaceuticals competitors?

    Competitors of NGM Biopharmaceuticals include Scynexis, vTv Therapeutics and Lixte Biotechnology.

  • Where is NGM Biopharmaceuticals headquarters?

    NGM Biopharmaceuticals headquarters is located at 333 Oyster Point Blvd, South San Francisco.

  • Where are NGM Biopharmaceuticals offices?

    NGM Biopharmaceuticals has an office in South San Francisco.

  • How many offices does NGM Biopharmaceuticals have?

    NGM Biopharmaceuticals has 1 office.